|
1
|
Okuda K, Fujimoto I, Hanai A and Urano Y:
Changing incidence of hepatocellular carcinoma in Japan. Cancer
Res. 47:4967–4972. 1987.PubMed/NCBI
|
|
2
|
Landis SH, Murray T, Bolden S and Wingo
PA: Cancer statistics. CA Cancer J Clin. 48:6–29. 1998.
|
|
3
|
El-Serag HB and Mason AC: Rising incidence
of hepatocellular carcinoma in the United States. N Engl J Med.
340:745–750. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Taylor-Robinson SD, Foster GR, Arora S,
Hargreaves S and Thomas HC: Increase in primary liver cancer in the
UK, 1979–1994. Lancet. 350:1142–1143. 1997.
|
|
5
|
Deuffic S, Poynard T, Buffat L and
Valleron AJ: Trends in primary liver cancer. Lancet. 351:214–215.
1998. View Article : Google Scholar
|
|
6
|
Okuda K, Ohtsuki T, Obata H, et al:
Natural history of hepatocellular carcinoma and prognosis in
relation to treatment. Study of 850 patients. Cancer. 56:918–928.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nagasue N, Yukaya H, Hamada T, Hirose S,
Kanashima R and Inokuchi K: The natural history of hepatocellular
carcinoma. A study of 100 untreated cases. Cancer. 54:1461–1465.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Boucher E, Corbinais S, Brissot P,
Boudjema K and Raoul JL: Treatment of hepatocellular carcinoma
(HCC) with systemic chemotherapy combining epirubicin, cisplatinum
and infusional 5-fluorouracil (ECF regimen). Cancer Chemother
Pharmacol. 50:305–308. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park SH, Lee Y, Han SH, et al: Systemic
chemotherapy with doxorubicin, cisplatin and capecitabine for
metastatic hepatocellular carcinoma. BMC Cancer. 6:32006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tzoracoleftherakis EE, Spiliotis JD,
Kyriakopoulou T and Kakkos SK: Intra-arterial versus systemic
chemotherapy for non-operable hepatocellular carcinoma.
Hepatogastroenterology. 46:1122–1125. 1999.PubMed/NCBI
|
|
11
|
Pohl J, Zuna I, Stremmel W and Rudi J:
Systemic chemotherapy with epirubicin for treatment of advanced or
multifocal hepatocellular carcinoma. Chemotherapy. 47:359–65. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Leung TW, Tang AM, Zee B, Yu SC, Lai PB,
Lau WY and Johnson PJ: Factors predicting response and survival in
149 patients with unresectable hepatocellular carcinoma treated by
combination cisplatin, interferon-alpha, doxorubicin and
5-fluorouracil chemotherapy. Cancer. 94:421–427. 2002. View Article : Google Scholar
|
|
13
|
Feun LG, O’Brien C, Molina E, et al:
Recombinant leukocyte interferon, doxorubicin, and 5FUDR in
patients with hepatocellular carcinoma-A phase II trial. J Cancer
Res Clin Oncol. 129:17–20. 2003.PubMed/NCBI
|
|
14
|
Patt YZ, Hassan MM, Lozano RD, Brown TD,
Vauthey JN, Curley SA and Ellis LM: Phase II trial of systemic
continuous fluorouracil and subcutaneous recombinant interferon
Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol.
21:421–427. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Levy I and Sherman M: The Liver Cancer
Study Group of the University of Toronto: Staging of hepatocellular
carcinoma: assessment of the CLIP, Okuda and Child-Pugh staging
systems in a cohort of 257 patients in Toronto. Gut. 50:881–885.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cho YK, Kim JK, Kim MY, Rhim H and Han JK:
Systemic review of randomized trials for hepatocellular carcinoma
treated with percutaneous ablation therapies. Hepatology.
49:453–459. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Epirubicin Study Group for Hepatocellular
Carcinoma. intra-arterial administration of epirubicin in the
treatment of nonresectable hepatocellular carcinoma. Epirubicin
Study Group for Hepatocellular Carcinoma. Cancer Chemother
Pharmacol. 19:183–189. 1987.
|
|
18
|
Ikeda M, Okusaka T, Ueno H, Morizane C,
Iwasa S, Hagihara A and Kojima Y: Hepatic arterial infusion
chemotherapy with epirubicin in patients with advanced
hepatocellular carcinoma and portal vein tumor thrombosis.
Oncology. 72:188–193. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yoshikawa M, Ono N, Yodono H, Ichida T and
Nakamura H: Phase II study of hepatic arterial infusion of a
fine-powder formulation of cisplatin for advanced hepatocellular
carcinoma. Hepatol Res. 38:474–483. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kondo M, Morimoto M, Numata K, Nozaki A
and Tanaka K: Hepatic arterial infusion therapy with a fine powder
formulation of Cisplatin for advanced hepatocellular carcinoma with
portal vein tumor thrombosis. Jpn J Clin Oncol. 41:69–75. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakakuma K, Tashiro S, Hiraoka T, Uemura
K, Konno T, Miyauchi Y and Yokoyama I: Studies on anticancer with
an oily anticancer drug injected into the ligated feeding hepatic
artery for liver cancer. Cancer. 52:2193–2200. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshikawa M, Saisho H, Ebara M, et al: A
randomized trial of intrahepatic arterial infusion of
4′-epidoxorubicin with Lipiodol versus 4′-epidoxorubicin alone in
the treatment of hepato- cellular carcinoma. Cancer Chemother
Pharmaco1. 33:S149–S152. 1994.
|
|
23
|
Ikeda M, Maeda S, Ashihara H, Nagahama H,
Tanaka M and Sasaki Y: Transcatheter arterial infusion chemotherapy
with cisplatin-lipiodol suspension in patients with hepatocellular
carcinoma. J Gastroenterol. 45:60–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Boucher E, Garin E, Guylligomarc’h A,
Olivié D, Boudjema K and Raoul JL: Intra-arterial injection of
iodine-131-labeled lipiodol for treatment of hepatocellular
carcinoma. Radiother Onco1. 82:76–82. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Okusaka T, Okada S, Nakanishi T, Fujiyama
S and Kubo Y: Phase II trial of intra-arterial chemotherapy using a
novel lipophilic platinum derivative (SM-11355) in patients with
hepatocellular carcinoma. Invest New Drugs. 22:169–176. 2004.
View Article : Google Scholar
|
|
26
|
Chaudhuri NK, Montag BJ and Heidelberger
C: Studies on fluorinated pyrimidines. III The metabolism of
5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo. Cancer
Res. 18:318–328. 1958.PubMed/NCBI
|
|
27
|
Ando E, Tanaka M, Yamashita F, et al:
Hepatic arterial infusion chemotherapy for advanced hepatocellular
carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Cancer. 95:588–595. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Okuda K, Tanaka M, Shibata J, et al:
Hepatic arterial infusion chemotherapy with continuous low-dose
administration of cisplatin and 5-fluorouracil for multiple
recurrence of hepatocellular carcinoma after surgical treatment.
Onco1 Rep. 6:587–591. 1999.
|
|
29
|
Tanioka H, Tsuji A, Morita S, et al:
Combination chemotherapy with continuous 5-fluorouracil and
1ow-dose cisplatin infusion for advanced hepatocellular carcinoma.
Anticancer Res. 23:1891–1897. 2003.PubMed/NCBI
|
|
30
|
Ueshima K, Kudo M, Takita M, et al:
Hepatic arterial infusion chemotherapy using low-dose
5-fluorouracil and cisplatin for advanced hepatocellular carcinoma.
Oncology. 78:1148–1153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yano H, Iemura A, Haramaki M, Ogasawara S,
Takayama A, Akiba J and Kojiro M: Interferon alfa receptor
expression and growth inhibition by interferon alfa in human liver
cancer cell lines. Hepatology. 29:1708–1717. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sakon M, Nagano H, Dono K, et al: Combined
intraarteria1 5-fluorouracil and subcutaneous interferon-alpha
therapy for advanced hepatocellular carcinoma with tumor thrombi in
the major portal branches. Cancer. 94:435–442. 2002. View Article : Google Scholar
|
|
33
|
Ota H, Nagano H, Sakon M, et al: Treatment
of hepatocellular carcinoma with major portal vein thrombosis by
combined therapy with subcutaneous interferon-alpha and
intra-arteria1 5-fluorouracil: role of type l interferon receptor
expression. Br J Cancer. 93:557–564. 2005. View Article : Google Scholar
|
|
34
|
Obi S, Yoshida H, Toune R, et al:
Combination therapy of intraarteria1 5-fluorouracil and systemic
interferon-alpha for advanced hepatocellular carcinoma with portal
venous invasion. Cancer. 106:1990–1997. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Enjoji M, Morizono S, Kotoh K, Kohjima M,
Miyagi Y, Yoshimoto T and Nakamuta M: Re-evaluation of antitumor
effects of combination chemotherapy with interferon-alpha and
5-fluorouracil for advanced hepatocellular carcinoma. World J
Gastroenterol. 11:5685–5687. 2005.PubMed/NCBI
|
|
36
|
Kuroda M, Kobayashi Y, Urawa N, et al:
Hepatic arterial infusion of 5-fluorouracil in combination with
subcutaneous interferon-alpha for advanced hepatocellular
carcinoma. Hepatogastroenterology. 54:518–521. 2007.PubMed/NCBI
|
|
37
|
Obora A, Shiratori Y, Okuno M, et al:
Synergistic induction of apoptosis by acyclic retinoid and
interferon-beta in human hepatocellular carcinoma cells.
Hepatology. 36:1115–1124. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ueda H: A randomized study of arterial
infusion chemotherapy for hepatocellular carcinoma: Low-dose
5-fluorouracil/cisplatin versus low-dose
5-fluorouracil/cisplatin/Interferon beta. J Clin Oncol.
25:18S2007.
|
|
39
|
Cheng AL, Kang YK, Chen Z, et al: Efficacy
and safety of sorafenib in patients in the Asia-Pacific region with
advanced hepatocellular carcinoma: a phase III randomised,
double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34.
2009. View Article : Google Scholar
|
|
40
|
Guan YS and He Q: Sorafenib: activity and
clinical application in patients with hepatocellular carcinoma.
Expert Opin Pharmacother. 12:303–313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang T, Ding X, Wei D, Cheng P, Su X, Liu
H, Wang D and Gao H: Sorafenib improves the survival of patients
with advanced hepatocellular carcinoma: a meta-analysis of
randomized trials. Anticancer Drugs. 21:326–332. 2010. View Article : Google Scholar : PubMed/NCBI
|
